The investigated safety concern for GLP-1 receptor agonist use was based on spontaneous reports of suicidal thoughts and thoughts of self-harm.1 To cover a wider range of conditions and outcomes associated with thoughts of self-harm and suicide,25,26 we assessed suicide death, suicide death and nonfatal self-harm, and self-harm and incident depression and anxiety-related disorders. This evidence concerns the gene GLP1R and major depressive disorder.